Takeda Pharmaceutical Co. $TAK Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC increased its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 14.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,989,100 shares of the company’s stock after acquiring an additional 370,800 shares during the quarter. Renaissance Technologies LLC’s holdings in Takeda Pharmaceutical were worth $55,358,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Private Trust Co. NA boosted its stake in Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares during the period. Parkside Financial Bank & Trust raised its position in shares of Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after purchasing an additional 1,684 shares during the period. SHP Wealth Management acquired a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $42,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock worth $55,000 after purchasing an additional 1,292 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a report on Wednesday, April 8th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $17.23 on Monday. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90. The company has a market cap of $55.22 billion, a PE ratio of 44.19 and a beta of -0.07. The stock has a 50 day simple moving average of $16.17 and a 200-day simple moving average of $17.03. The company has a current ratio of 1.09, a quick ratio of 0.60 and a debt-to-equity ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. On average, equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.12 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.